8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Apr 3, 2026·SEC
Material company update
Mar 30, 2026·SEC
Kezar Life Sciences, Inc.(KZR)Earnings, Financials & Key Ratios
KZR•NASDAQ
Price updated May 25, 2026
AboutKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$51M+42.6%
- Net Income-$56M+33.1%
- EPS (Diluted)-7.66-566.1%
- ROE-59.93%-9.0%
- ROIC-85.35%-64.8%
- Debt/Equity0.03-76.0%
KZR Key Insights
Kezar Life Sciences, Inc. (KZR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 82 (top 18%)
- ✓Share count reduced 90.0% through buybacks
- ✓Trading near 52-week high
- ✓Trading at only 0.8x book value
✗Weaknesses
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when KZR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KZR Price & Volume
Kezar Life Sciences, Inc. (KZR) stock price & volume — 10-year historical chart
Loading chart...
KZR Growth Metrics
Kezar Life Sciences, Inc. (KZR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM42.48%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-9.79%
Return on Capital
10 Years-43.14%
5 Years-42.74%
3 Years-51.44%
Last Year-53.77%
KZR Recent Earnings
Kezar Life Sciences, Inc. (KZR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
May 11, 2026EPS
$0.78
Est $0.98
+20.4%
Revenue
—
Est $1M
Q2 2026
Mar 27, 2026EPS
$1.99
Est $1.31
-52.0%
Revenue
—
Est $333,330
Q4 2025
Nov 12, 2025EPS
$1.53
Est $1.81
+15.5%
Revenue
—
Q3 2025
Aug 13, 2025EPS
$1.87
Est $2.15
+13.0%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.78vs $0.98+20.4% | —vs $1M |
| Q2 2026 | Mar 27, 2026 | $1.99vs $1.31-52.0% | —vs $333,330 |
| Q4 2025 | Nov 12, 2025 | $1.53vs $1.81+15.5% | — |
| Q3 2025 | Aug 13, 2025 | $1.87vs $2.15+13.0% | — |
Based on last 12 quarters of dataView full earnings history →
KZR Peer Comparison
Kezar Life Sciences, Inc. (KZR) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 6.9B | 33.62 | -12.14 | -68.16% | 0.00 | |||
 ARQT | 3.05B | 24.38 | -187.54 | 91.34% | -0.57% | -1.41% | 0.03 | |
 PRAX | 7.7B | 266.54 | -19.77 | -100% | -43.02% | 0.00 | ||
 TGTX | 7.58B | 49.52 | 17.88 | 87.32% | 65.95% | 87.36% | 0.40 | |
 CABA | 490.79M | 3.01 | -1.84 | -131.58% | 0.24 | |||
 RCUS | 2.4B | 23.80 | -7.23 | -4.26% | -156.36% | -68.97% | 0.16 | |
 HRMY | 1.99B | 34.46 | 12.72 | 21.51% | 16.2% | 17.19% | 0.28 | |
 VKTX | 3.33B | 28.75 | -9.01 | -71.31% | 0.00 |
Compare KZR vs Peers
Kezar Life Sciences, Inc. (KZR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KZR Income Statement
Kezar Life Sciences, Inc. (KZR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 7M | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | -100% | - | - |
Cost of Goods Sold | 175K | 690K | 1.3M | 1.54M | 1.51M | 0 | 0 | 0 | 897K | 176K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -175K▲ 0% | -690K▼ 294.3% | -1.3M▼ 88.6% | -1.54M▼ 18.7% | -1.51M▲ 2.2% | 0▲ 100.0% | 7M▲ 0% | 0▼ 100.0% | -897K▲ 0% | -176K▲ 0% |
Gross Margin % | - | - | - | - | - | - | 100% | - | - | - |
Gross Profit Growth % | -13.64% | -294.29% | -88.55% | -18.68% | 2.2% | 100% | - | -100% | - | - |
Operating Expenses | 8.75M | 24.73M | 36.68M | 41.46M | 53.15M | 71.16M | 118.42M | 90.61M | 51.37M | 41.83M |
OpEx % of Revenue | - | - | - | - | - | - | 1691.77% | - | - | - |
Selling, General & Admin | 2.28M | 6.59M | 8.68M | 10.43M | 15.72M | 20.15M | 26.54M | 23.39M | 18.51M | 18.27M |
SG&A % of Revenue | - | - | - | - | - | - | 379.14% | - | - | - |
Research & Development | 6.47M | 18.14M | 28M | 31.04M | 38.94M | 51.01M | 85.7M | 65.74M | 33.76M | 23.12M |
R&D % of Revenue | - | - | - | - | - | - | 1224.24% | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | -1.51M | 0 | 6.19M | 1.47M | -897K | 436K |
Operating Income | -8.75M▲ 0% | -24.73M▼ 182.6% | -37.98M▼ 53.6% | -43.01M▼ 13.2% | -54.66M▼ 27.1% | -71.16M▼ 30.2% | -111.42M▼ 56.6% | -90.61M▲ 18.7% | -52.27M▲ 42.3% | -42.01M▲ 0% |
Operating Margin % | - | - | - | - | - | - | -1591.77% | - | - | - |
Operating Income Growth % | 2.68% | -182.62% | -53.59% | -13.25% | -27.09% | -30.19% | -56.58% | 18.68% | 42.31% | - |
EBITDA | -8.57M | -24.04M | -36.68M | -41.46M | -53.15M | -70.14M | -110.36M | -89.56M | -51.37M | -41.36M |
EBITDA Margin % | - | - | - | - | - | - | -1576.54% | - | - | - |
EBITDA Growth % | 2.97% | -180.34% | -52.59% | -13.05% | -28.18% | -31.97% | -57.34% | 18.84% | 42.64% | 50.46% |
D&A (Non-Cash Add-back) | 175K | 690K | 1.3M | 1.54M | 1.51M | 1.02M | 1.07M | 1.04M | 897K | 646K |
EBIT | -8.52M | -23.17M | -35.72M | -41.8M | -54.47M | -67.05M | -100.32M | -82.14M | -52.27M | -32.42M |
Net Interest Income | 0 | 0 | 2.25M | 1.21M | 29K | 2.92M | 9.55M | 6.87M | 4.44M | 2.18M |
Interest Income | 232K | 1.56M | 2.25M | 1.21M | 188K | 4.11M | 11.1M | 8.46M | 4.44M | 3.63M |
Interest Expense | 0 | 0 | 0 | 0 | 159K | 1.19M | 1.55M | 1.59M | 0 | 840K |
Other Income/Expense | 232K | 1.56M | 2.25M | 1.21M | 29K | 2.92M | 9.55M | 6.87M | -3.76M | -3.23M |
Pretax Income | -8.52M▲ 0% | -23.17M▼ 172.0% | -35.72M▼ 54.2% | -41.8M▼ 17.0% | -54.63M▼ 30.7% | -68.24M▼ 24.9% | -101.87M▼ 49.3% | -83.74M▲ 17.8% | -56.03M▲ 33.1% | -45.23M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | -1455.29% | - | - | - |
Income Tax | 0 | 0 | -635K | -58K | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 1.78% | 0.14% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -8.52M▲ 0% | -23.17M▼ 172.0% | -35.09M▼ 51.5% | -41.74M▼ 19.0% | -54.63M▼ 30.9% | -68.24M▼ 24.9% | -101.87M▼ 49.3% | -83.74M▲ 17.8% | -56.03M▲ 33.1% | -45.23M▲ 0% |
Net Margin % | - | - | - | - | - | - | -1455.29% | - | - | - |
Net Income Growth % | 5.26% | -172.01% | -51.45% | -18.97% | -30.88% | -24.91% | -49.28% | 17.8% | 33.08% | 42.48% |
Net Income (Continuing) | -8.52M | -23.17M | -35.09M | -41.74M | -54.63M | -68.24M | -101.87M | -83.74M | -56.03M | -45.23M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.65▲ 0% | -1.22▼ 87.7% | -1.65▼ 35.2% | -0.95▲ 42.4% | -1.04▼ 9.5% | -1.01▲ 2.9% | -1.40▼ 38.6% | -1.15▲ 17.9% | -7.66▼ 566.1% | -6.16▲ 0% |
EPS Growth % | 5.8% | -87.69% | -35.25% | 42.42% | -9.47% | 2.88% | -38.61% | 17.86% | -566.09% | -9.79% |
EPS (Basic) | -0.65 | -1.22 | -1.65 | -0.95 | -1.04 | -1.01 | -1.40 | -1.15 | -7.66 | - |
Diluted Shares Outstanding | 13.02M | 19.02M | 19.08M | 44M | 52.76M | 67.37M | 72.55M | 72.9M | 7.32M | 7.34M |
Basic Shares Outstanding | 13.02M | 19.02M | 19.08M | 44M | 52.76M | 67.37M | 72.55M | 72.9M | 7.32M | 7.34M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
KZR Balance Sheet
Kezar Life Sciences, Inc. (KZR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 52.33M | 109.81M | 81.13M | 144.81M | 211.65M | 285.72M | 206.95M | 137.49M | 75.73M | 67.56M |
Cash & Short-Term Investments | 51.03M | 107.43M | 78.21M | 140.45M | 208.35M | 276.56M | 201.37M | 132.25M | 71.88M | 66.23M |
Cash Only | 51.03M | 24.18M | 14.95M | 21.23M | 62.88M | 40.46M | 35.49M | 41.75M | 71.88M | 66.23M |
Short-Term Investments | 0 | 83.25M | 63.26M | 119.22M | 145.47M | 236.1M | 165.88M | 90.5M | 0 | 0 |
Accounts Receivable | 0 | 0 | 642K | 766K | 0 | 0 | 2.29M | 424K | 1.93M | 0 |
Days Sales Outstanding | - | - | - | - | - | - | 119.46 | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 508K | 489K | 406K | 865K | 729K | 0 | 251K | 351K | 1.39M | 1.33M |
Total Non-Current Assets | 1.9M | 4.88M | 8.38M | 7.03M | 6.28M | 13.85M | 14.29M | 7.19M | 915K | 436K |
Property, Plant & Equipment | 1.54M | 4.59M | 8.1M | 6.75M | 6M | 13.17M | 8.69M | 4.78M | 915K | 436K |
Fixed Asset Turnover | - | - | - | - | - | - | 0.81x | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 13K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 343K | 282K | 282K | 282K | 282K | 674K | 5.59M | 2.42M | 0 | 0 |
Total Assets | 54.22M▲ 0% | 114.68M▲ 111.5% | 89.51M▼ 21.9% | 151.84M▲ 69.6% | 217.93M▲ 43.5% | 299.57M▲ 37.5% | 221.24M▼ 26.1% | 144.68M▼ 34.6% | 76.65M▼ 47.0% | 68M▲ 0% |
Asset Turnover | - | - | - | - | - | - | 0.03x | - | - | 0.00x |
Asset Growth % | 374.63% | 111.5% | -21.95% | 69.63% | 43.53% | 37.46% | -26.15% | -34.6% | -47.02% | -172.53% |
Total Current Liabilities | 1.48M | 3.34M | 6M | 6.44M | 8.21M | 11M | 17.74M | 20.33M | 6.57M | 2.76M |
Accounts Payable | 547K | 193K | 823K | 2.36M | 2.03M | 2.48M | 8.25M | 3.65M | 507K | 273K |
Days Payables Outstanding | 1.14K | 102.09 | 230.9 | 557.43 | 490.21 | - | - | - | 206.3 | 1.48K |
Short-Term Debt | 0 | 0 | 900K | 1.04M | 0 | 0 | 3.01M | 5.22M | 2.33M | 1.35M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 515K | 2.41M | 2.99M | 1.69M | 1.97M | 2.69M | 2.77M | 5.22M | 3.67M | 1.14M |
Current Ratio | 35.26x | 32.91x | 13.52x | 22.48x | 25.77x | 25.98x | 11.66x | 6.76x | 11.52x | 24.46x |
Quick Ratio | 35.26x | 32.91x | 13.52x | 22.48x | 25.77x | 25.98x | 11.66x | 6.76x | 11.52x | 24.46x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 78.42M | 2.55M | 5.46M | 4.42M | 12.85M | 18.7M | 15.92M | 7.44M | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 9.62M | 9.83M | 10.07M | 5.11M | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 5.46M | 4.42M | 3.22M | 8.87M | 5.85M | 2.33M | 0 | 344K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 78.42M | 2.55M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 79.91M | 5.88M | 11.47M | 10.86M | 21.06M | 29.7M | 33.66M | 27.77M | 6.57M | 2.76M |
Total Debt | 0 | 0 | 6.36M | 5.46M | 14.04M | 21.26M | 18.93M | 16.18M | 2.33M | 1.35M |
Net Debt | -51.03M | -24.18M | -8.59M | -15.76M | -48.84M | -19.19M | -16.56M | -25.57M | -69.55M | -64.88M |
Debt / Equity | - | - | 0.08x | 0.04x | 0.07x | 0.08x | 0.10x | 0.14x | 0.03x | 0.02x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.03x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.57x |
Interest Coverage | - | - | - | - | -342.58x | -56.59x | -64.72x | -51.56x | - | -38.59x |
Total Equity | -25.69M▲ 0% | 108.8M▲ 523.5% | 78.05M▼ 28.3% | 140.98M▲ 80.6% | 196.88M▲ 39.7% | 269.87M▲ 37.1% | 187.57M▼ 30.5% | 116.92M▼ 37.7% | 70.07M▼ 40.1% | 65.24M▲ 0% |
Equity Growth % | -47.39% | 523.55% | -28.26% | 80.63% | 39.65% | 37.08% | -30.5% | -37.67% | -40.07% | -153.96% |
Book Value per Share | -1.97 | 5.72 | 4.09 | 3.20 | 3.73 | 4.01 | 2.59 | 1.60 | 9.58 | 8.88 |
Total Shareholders' Equity | -25.69M | 108.8M | 78.05M | 140.98M | 196.88M | 269.87M | 187.57M | 116.92M | 70.07M | 65.24M |
Common Stock | 1K | 19K | 19K | 46K | 56K | 68K | 73K | 7K | 7K | 7K |
Retained Earnings | -26.03M | -49.2M | -84.28M | -126.02M | -180.65M | -248.89M | -350.76M | -434.5M | -490.53M | -496.29M |
Treasury Stock | -451K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -111K | -203K | -196K | -137K | -291K | -923K | -130K | -162K | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KZR Cash Flow Statement
Kezar Life Sciences, Inc. (KZR) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -8.11M | -20.79M | -29.88M | -36.95M | -42.44M | -58.85M | -81.64M | -74.21M | -51.78M | -42.03M |
Operating CF Margin % | - | - | - | - | - | - | -1166.36% | - | - | - |
Operating CF Growth % | 16.92% | -156.41% | -43.69% | -23.67% | -14.85% | -38.67% | -38.74% | 9.1% | 30.23% | 154.27% |
Net Income | -8.52M | -23.17M | -35.09M | -41.74M | -54.63M | -68.24M | -101.87M | -83.74M | -56.03M | -45.23M |
Depreciation & Amortization | 175K | 690K | 1.3M | 1.54M | 1.51M | 1.02M | 1.07M | 1.04M | -1.1M | 561K |
Stock-Based Compensation | 203K | 1.99M | 4.01M | 4.94M | 7.6M | 14.01M | 18.14M | 13.01M | 8.96M | 6.84M |
Deferred Taxes | 0 | 0 | 0 | 0 | 1.77M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 472K | -370K | -979K | 317K | 91K | -1.18M | -3.68M | -3.23M | 1.8M | -1.93M |
Working Capital Changes | 30K | 62K | 881K | -2.01M | 1.23M | -4.46M | 4.71M | -1.3M | -5.4M | -2.27M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 81K | 1.44M | 2.21M | 313K | 1.22M | 1.81M | 6.35M | -3.15M | -7.34M | -6.58M |
Cash from Investing | -389K | -83.9M | 20.42M | -56.5M | -28.44M | -91.39M | 76.05M | 80.43M | 92.46M | 80.25M |
Capital Expenditures | -389K | -1.12M | -607K | -194K | -316K | -1.58M | -1.81M | -29K | -8K | 0 |
CapEx % of Revenue | - | - | - | - | - | - | 25.86% | - | - | - |
Acquisitions | 0 | 10K | -21.03K | 56.3K | 28.13K | 89.81K | 0 | 0 | 121K | 121K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 10K | 21.03K | -56.3K | -28.13K | -89.81K | 5K | 0 | 0 | 1.53M |
Cash from Financing | 49.76M | 77.91M | 272K | 99.64M | 112.58M | 127.86M | 638K | 103K | -10.59M | -9.01M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 9.53M | 0 | 0 | 0 | -10.65M | -9.35M |
Equity Issued (Net) | 49.76M | 77.91M | 272K | 99.19M | 100.97M | 126.54M | 638K | 103K | 65K | 65K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 456K | 2.08M | 1.32M | 0 | 0 | 0 | 267K |
Net Change in Cash | 41.29M▲ 0% | -26.86M▼ 165.1% | -9.23M▲ 65.6% | 6.28M▲ 168.0% | 41.65M▲ 563.6% | -22.43M▼ 153.8% | -4.96M▲ 77.9% | 6.26M▲ 226.1% | 30.13M▲ 381.6% | 29.23M▲ 0% |
Free Cash Flow | -8.5M▲ 0% | -21.91M▼ 157.8% | -30.48M▼ 39.1% | -37.14M▼ 21.8% | -42.75M▼ 15.1% | -60.42M▼ 41.3% | -83.45M▼ 38.1% | -74.24M▲ 11.0% | -51.78M▲ 30.2% | -42.03M▲ 0% |
FCF Margin % | - | - | - | - | - | - | -1192.21% | - | - | - |
FCF Growth % | 14.09% | -157.85% | -39.12% | -21.84% | -15.1% | -41.33% | -38.12% | 11.04% | 30.25% | 38.71% |
FCF per Share | -0.65 | -1.15 | -1.60 | -0.84 | -0.81 | -0.90 | -1.15 | -1.02 | -7.08 | -5.72 |
FCF Conversion (FCF/Net Income) | 0.95x | 0.90x | 0.85x | 0.89x | 0.78x | 0.86x | 0.80x | 0.89x | 0.92x | 0.93x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KZR Key Ratios
Kezar Life Sciences, Inc. (KZR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -55.75% | -37.56% | -38.12% | -32.34% | -29.24% | -44.54% | -55% | -59.93% | -58.35% |
| Return on Invested Capital (ROIC) | - | -469.78% | -36.97% | -33.14% | -30% | -26.77% | -39.63% | -51.8% | -85.35% | -101.36% |
| Gross Margin | - | - | - | - | - | - | 100% | - | - | - |
| Net Margin | - | - | - | - | - | - | -1455.29% | - | - | - |
| Debt / Equity | - | - | 0.08x | 0.04x | 0.07x | 0.08x | 0.10x | 0.14x | 0.03x | 0.02x |
| Interest Coverage | - | - | - | - | -342.58x | -56.59x | -64.72x | -51.56x | - | -38.59x |
| FCF Conversion | 0.95x | 0.90x | 0.85x | 0.89x | 0.78x | 0.86x | 0.80x | 0.89x | 0.92x | 0.93x |
| Revenue Growth | - | - | - | - | - | - | - | -100% | - | - |
Related:KZR Dividend History·KZR Revenue History·KZR Price History·KZR P/E History·KZR Financial Ratios·KZR Institutional Holders
KZR SEC Filings & Documents
Kezar Life Sciences, Inc. (KZR) SEC filings — annual & quarterly reports (10-K, 10-Q)
KZR Frequently Asked Questions
Kezar Life Sciences, Inc. (KZR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Kezar Life Sciences, Inc. (KZR) grew revenue by 0.0% over the past year. Growth has been modest.
Kezar Life Sciences, Inc. (KZR) reported a net loss of $45.2M for fiscal year 2025.
Dividend & Returns
Kezar Life Sciences, Inc. (KZR) has a return on equity (ROE) of -59.9%. Negative ROE indicates the company is unprofitable.
Kezar Life Sciences, Inc. (KZR) had negative free cash flow of $42.0M in fiscal year 2025, likely due to heavy capital investments.